Health Technology Assessment (HTA)

  • HTA underlies the decisions that are made by payers and clinical societies setting guidelines – who are often the final gatekeepers as to whether a technology gets to providers and patients.

  • Taking into account the safety, clinical- and cost-effectiveness, and often even social, ethical, and legal aspects of implementing a medical technology, these evidence-based assessments provide the framework to determine whether costs of a technology are justified by their value.

  • HTA practices vary significantly, and the same exact evidence can be assessed and valued completely differently by different payers; presenting the right types and levels of evidence to each individual payer is critical.

  • HTA can be performed multiple times for a single technology: during market introduction, once the target population of the technology has increased significantly, and/or when new evidence is generated that might change conclusions of the original assessment.

  • In the US, there is no national HTA program or even a standardized approach to HTA; each private and public health insurer performs their own internal assessments, creating a very subjective approach lacking clear definition of the role of HTA in healthcare decision making.

  • In addition to clinical societies, private health insurers and government payers, many other stakeholders utilize outputs from HTA including patients, caregivers, providers, and healthcare facilities, amongst others.

  • Experts in HTA frameworks and the types and levels of evidence required for HTA, we utilize SMART (short-term, meaningful, attainable, real-world, and triangulated) evidence generation strategies to generate the evidence needed to support HTA.

  • Following a three-phased approach, our experts can perform health economic modeling built around the quadruple aim of healthcare (better patient outcomes, improved clinician experiences, lower costs, and improved patient experiences) to convey value from the facility and payer perspective (in terms of budgetary impact, cost-effectiveness and cost-benefit of your technology) and support HTA.

  • We can conduct clinical-economic studies leveraging patient billing data from facilities participating in your studies or supplemental, real-world data sources to generate the robust clinical-economic evidence you need.


Related Solutions

Stethoscope sitting on a clipboard showing payer reimbursement for a medical device.

Reimbursement Support

Medical Key Opinion Leaders (KOLs) walking down a hospital hallway discussing new medical technology.

KOL Identification

Stethoscope sitting on medical insurance reimbursement documents.

Payer Engagement

Generate Your Most Impactful Evidence

Contact our experts for HTA support to achieve maximal market access for your technology.

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.
Go to Top